17:00 , Jan 12, 2018 |  BC Week In Review  |  Company News

Regeneron leads big data sequencing effort

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced a consortium of six biotech and pharmas to speed up exome sequencing of genetic data from samples in the UK Biobank. UK Biobank debuted in 2012 with blood, urine and saliva...
23:27 , Jan 8, 2018 |  BC Extra  |  Company News

Regeneron leads big data sequencing effort

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced a consortium of six biotech and pharmas to speed up exome sequencing of genetic data from samples in the UK Biobank. UK Biobank debuted in 2012 with blood, urine and saliva...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Cytox sales and marketing update

Cytox launched its variaTECT SNP array genetic biomarker test and SNPfitR analysis software ito diagnose Alzheimer’s disease by determining amyloid positive patients from blood or archived samples. Cytox said Affymetrix Inc. will begin formal...
07:00 , Aug 8, 2016 |  BC Extra  |  Company News

Management tracks

Suneva Medical Inc. (San Diego, Calif.) said chairman and CEO Nicholas Teti resigned. The dermatology company promoted Preston Romm to president and CEO from COO. Synthetic biology company Intrexon Corp. (NYSE:XON) hired Andrew Last as...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Affymetrix, Origin Technologies deal

Origin withdrew its proposal to acquire Affymetrix for $17 per share. Origin said Affymetrix countered Origin’s proposal with “unreasonable demands and timeline.” On March 31, Thermo Fisher Scientific Inc. (NYSE:TMO, Waltham, Mass.) completed its...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Affymetrix, Thermo Fisher deal

Thermo Fisher completed its acquisition of Affymetrix for $14 per share, or about $1.3 billion. Affymetrix’s board recommended Thermo Fisher’s bid to shareholders after evaluating the proposal by Origin Technologies Corp. LLC (Palo Alto,...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Company News

Affymetrix, Origin Technologies deal

Cellular and genetic analysis tools company Affymetrix said it will engage with Origin to discuss Origin’s increased proposal to acquire Affymetrix. Origin originally proposed on March 18 to acquire Affymetrix for $16.10 per share in...
01:11 , Mar 22, 2016 |  BC Extra  |  Company News

Affymetrix spurning former execs' buyout offer

Affymetrix Inc. (NASDAQ:AFFX) said its board rejected a proposal from Origin Technologies Corp. LLC, a shell company founded by former Affymetrix executives, to acquire the tools company for about $1.5 billion. Affymetrix's board reiterated its...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Affymetrix, Thermo Fisher deal

Thermo Fisher will acquire cellular and genetic analysis tools company Affymetrix for $14 per share in cash, or about $1.3 billion. The price is a 52% premium to Affymetrix’s close of $9.21 on Jan. 8,...
08:00 , Jan 18, 2016 |  BioCentury  |  Finance

Conference weak

This year's JPMorgan Healthcare Conference was marred by the biotech sector's worst conference week performance in more than two decades. But if 2016 is off to a dire start, at least one buysider and a...